Anti-ENA6 Plus DFS70Ab Profile

Anti-ENA6 Plus DFS70 is designed to facilitate the proper triage of patients with positive Anti-Nuclear Antibodies (ANA) by identifying those most likely to benefit from a rheumatology specialist. It detects the novel Anti-DFS70 along with 6 other clinically useful autoantibodies to ENA, which may help identify systemic lupus erythematous (SLE), mixed connective tissue disease (MCTD), Sjogren's, systemic sclerosis, and idiopathic inflammatory myopathy (IIM). Positive Anti-DFS70 antibodies in isolation may help identify individuals who do not have an AARD (ANA-associated rheumatic disease), especially in the absence of significant clinical findings.

Anti-DFS70 Abs confer a likelihood ratio for the absence of systemic autoimmune rheumatic disease of 10.9 and are detectable in 2% to 22% of healthy individuals and in less than 1% of patients with AARD.